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DOI: 10.1016/j.ajpath.2011.04.001This Month in AJPCAR Drives to Sites of Pulmonary
Hypertension
Pulmonary arterial hypertension (PAH), defined by ele-
vated pulmonary vascular resistance, eventually leads to
right heart failure and premature death. To combat a lack
of selective targeted therapy, Urakami et al (Am J Pathol
2011, 178:2489–2495) investigated the cyclic peptide
CARSKNKDC (CAR). When intravenously administered
to PAH rats, CAR accumulated in experimentally induced
hypertensive lungs but not in healthy tissue. CAR homed
to all layers of remodeled pulmonary arteries and to cap-
illary vessels and interstitial space of the PAH lungs,
suggesting the clinical utility of CAR in the targeted de-
livery of therapeutic compounds to PAH lungs.
Edema Toxin and Anthrax—Seeing Is
Believing
Noninvasive imaging techniques enable real-time track-
ing of pathogen-host interactions in vivo. Dumetz et al
(Am J Pathol 2011, 178:2523–2535) visualized wild-type
Bacillus anthracis in guinea pig and mouse hosts by using
bioluminescence imaging coupled with histology. Edema
toxin (ET), but not lethal toxin (LT), markedly modified the
patterns of bacterial dissemination, with direct dissemi-
nation to the spleen and apoptosis of lymphoid cells.
When produced together during infection, early lesions
were typical of LT, whereas later lesions, of ET. These
data propose a greater role than previously suspected for
ET in anthrax, suggesting that therapeutic targeting of ET
may contribute to protection.
Adiponectin and PPAR in Stellate Cell
Activation
Altered hepatic pathology, function, or both are common
sequelae of the metabolic syndrome. Shafiei et al (Am J
Pathol 2011, 178:2690–2699) asked how adiponectin
modulates hepatic stellate cell activation and fibrogen-
esis using transgenic mouse models. Mice overexpress-
ing adiponectin were resistant to experimental fibrosis
whereas adiponectin-null animals developed severe fi-
brosis. In wild-type stellate cells overexpressing adi-
ponectin, mRNA expression of PPAR, SREBP1c, andCEBP was significantly increased. The PPAR agonist
troglitazone prevented upregulation of collagen 1(I) and
-SMA mRNA in wild-type stellate cells but had no effect
on adiponectin-null stellate cells. These findings eluci-
date the complicated relationship between PPAR and
adiponectin in stellate cell activation.
Restoring Immune Responses in
Ataxia-Telangiectasia
Ataxia-telangiectasia (A-T) patients and mice that lack
the protein kinase ATM exhibit immune system-related
pathology. Using the lymphocytic choriomeningitis virus
(LCMV) model, D’Souza et al (Am J Pathol 2011, 178:
2740–2751) found that ATM/ mice, despite having
fewer naïve CD8 T cells, effectively cleared the virus.
They observed aberrant CD8 T-cell responses, including
defective expansion and contraction, effector-to-memory
differentiation, and a switch in viral-epitope immunodomi-
nance. Inhibition of Akt or mTORC1 during T-cell receptor
activation alone rescued the proliferation defect, and rapa-
mycin treatment of ATM/ mice during LCMV infection
increased the number of memory T cells. Targeting Akt
and/or mTORC1 may thus be of therapeutic value in restor-
ing immune responses in A-T patients.
HNSCC Invasion Proceeds without
Macrophages
Invasion of tumor cells into the local stroma is an impor-
tant component in cancer progression. Smirnova et al
(Am J Pathol 2011, 178:2857–2865) examined in vivo
invasion of HNSCC cells in response to applied gradients
of epidermal growth factor (EGF) and the chemokine
CXCL12. Invading cells were 75% tumor cells, about
15% macrophages, and 10% unidentified cells. Al-
though macrophages were present, they were not re-
quired for HNSCC invasion. CXCL12-induced in vivo in-
vasion of HNSCC cells occurred via a unidirectional
transactivation of EGFR through CXCR4. CXCL12 activa-
tion of EGFR appeared to occur via release of EGFR
ligands. Thus, these data support treatment of HNSCC
with EGFR inhibitors to inhibit local invasion independent
of effects on tumor growth rate.
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